InnoCare Signs Research Deal With Lilly Worth Up to $3.35 Billion

InnoCare Pharma has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover and develop new medicines, the companies announced September 24, 2026.¹ InnoCare will leverage its proprietary drug discovery platform to discover and advance compounds against up to 5 targets addressing critical unmet medical needs, with Lilly responsible for subsequent development and commercialization.¹

"We are excited to leverage our R&D platform to collaborate with a global pharmaceutical leader like Lilly," said Jasmine Cui, PharmD, co-founder, chairwoman, and CEO of InnoCare, in a company press release.¹ "We are dedicated to expanding our partnership and innovation footprint."

What are the terms of the deal?

Under the agreement, InnoCare is eligible to receive up to $100 million in upfront and near-term payments, plus up to approximately $3.25 billion in development and commercial milestone payments, for a combined potential deal value of roughly $3.35 billion, along with single-digit tiered royalties on annual net product sales.¹ Financial terms beyond these figures, including specific initial disease targets, were not disclosed.¹

How does this deal fit into Lilly's broader business development strategy?

The InnoCare agreement follows a similar structure to other recent Lilly research collaborations with smaller biotechs, in which the partner leads early-stage target discovery and optimization while Lilly assumes responsibility for later-stage development, manufacturing, and commercialization.² In August 2026, for example, Lilly entered a comparable strategic research collaboration and licensing agreement with Amplitude Therapeutics to discover and develop trans-amplifying RNA vaccine candidates for infectious diseases, under which Amplitude leads early platform optimization before candidates advance into Lilly-led development.²

Speaking more broadly about why such structured collaborations have become central to biopharma R&D, Manisha P. Desai, PhD, senior vice president of product development at Bristol Myers Squibb, stated in a previous interview with BioPharm International®, an Industry Sciences 1 brand, "I think early alignment is very critical because development and manufacturing teams ... bring complementary sets of expertise to the table."³ As modalities grow more complex, no single organization can sustain all required capabilities in-house, Dr Desai noted, driving companies toward specialized partners that combine internal expertise with external technology and large-scale experience across many portfolios.³

What is InnoCare's current pipeline and momentum?

InnoCare has 3 approved drugs, orelabrutinib, tafasitamab, and zurletrectinib, more than 10 innovative drug candidates in clinical development, and multiple preclinical-stage programs, with operations in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the US.¹ In its 2026 interim results, InnoCare reported revenue growth of 55.5% to RMB 1.1 billion and a return to profitability, with profit of ¥239.7 million (US$35.71 million) in the first half of 2026, a turnaround from a loss in the same period the prior year.⁴ The company also recently received clinical trial approval in China for ICP-B381, a bispecific antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen and six transmembrane epithelial antigen of the prostate 1 for solid tumors, including prostate cancer. The candidate is the company’s first bispecific ADC and third ADC candidate to enter clinical development.⁵

What are the limitations?

The agreement's specific disease targets, therapeutic areas, and development timeline were not been disclosed. The milestone payments are contingent on clinical, regulatory, and commercial success and are not necessarily guaranteed.

References

1. InnoCare Pharma. InnoCare announces strategic research collaboration and license agreement with Lilly to develop new medicines. Press release. Published September 24, 2026. Accessed September 24, 2026. https://www.innocarepharma.com/m/en/news/activity/en020260924-InnoCare-Announces-Collaboration-with-Lilly
2. Amplitude Therapeutics. Amplitude Therapeutics and Lilly enter strategic collaboration to develop trans-amplifying RNA vaccines for infectious diseases. Press release. Published August 19, 2026. Accessed September 24, 2026. https://www.prnewswire.com/news-releases/amplitude-therapeutics-and-lilly-enter-strategic-collaboration-to-develop-trans-amplifying-rna-vaccines-for-infectious-diseases-302855610.html
3. Mirasol F, Desai MP. Drug Digest: Examining the growing role of partnerships in modern bioprocessing and biopharma R&D with Bristol Myers Squibb's Dr. Manisha P. Desai. BioPharm International. Published March 27, 2026. Accessed September 24, 2026. https://www.biopharminternational.com/view/drug-digest-examining-the-growing-role-of-partnerships-in-modern-bioprocessing-and-biopharma-r-d-with-bristol-myers-squibb-s-dr-manisha-p-desai
4. InnoCare Pharma. InnoCare reports 2026 interim results, sustained profitability and key milestones achieved. Press release. Published August 24, 2026. Accessed September 24, 2026. https://www.innocarepharma.com/en/news/activity/en020260824-InnoCare-2026-Interim-Results
5. InnoCare Pharma. InnoCare announces approval of clinical trial of novel bispecific ADC ICP-B381 targeting PSMA/STEAP1 in China. Press release. Published September 8, 2026. Accessed September 24, 2026. https://www.innocarepharma.com/en/news/activity/en020260909-IND-Approval-of-Bispecific-AD-ICP-B381